In a study of MSH2 in non-small cell lung cancer (NSCLC), no mutations were found while 29% of NSCLC had epigenetic reduction of MSH2 expression. In acute lymphoblastoid leukemia (ALL), no MSH2 mutations were found while 43% of ALL patients showed MSH2 promoter methylation and 86% of relapsed ALL patients had MSH2 promoter methylation.
In a study of MSH2 in non-small cell lung cancer (NSCLC), no mutations were identified while 29% of NSCLC had epigenetic reduction of MSH2 expression. In acute lymphoblastoid leukemia (ALL), no MSH2 mutations were found while 43% of ALL patients exhibited MSH2 promoter methylation and 86% of relapsed ALL patients showed MSH2 promoter methylation.